| Literature DB >> 12461520 |
Giuseppe Remuzzi1, Norberto Perico, Ariela Benigni.
Abstract
The discovery of endothelin--a highly potent endogenous vasoconstrictor - in 1988 has led to considerable efforts to develop antagonists of endothelin receptors that could have therapeutic potential in disorders including hypertension, heart failure and renal diseases. However, in general, the results of trials in humans have not mirrored the highly promising effects in animal disease models. Here, we discuss preclinical and clinical results with endothelin antagonists, and consider possible approaches to fully realizing the potential of endothelin antagonism.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12461520 DOI： 10.1038/nrd962
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694